Skip to content

Clinical study for the treatment of refractory sudden deafness by endotoscopy with tympanic tube pumping glucocorticoid and NGF

Clinical study for the treatment of refractory sudden deafness by endotoscopy with tympanic tube pumping glucocorticoid and NGF

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024785
Enrollment
Unknown
Registered
2019-07-27
Start date
2019-08-01
Completion date
Unknown
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory sudden deafness

Interventions

1:endotoscopic tympanic catheterization+ Medication ((Dexamethasone +NGF))
2:Medication (Dexamethasone +NGF)

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1 adults, aged 18 to 60 years; 2 unilateral sudden sensorineural deafness; 3 the course of sudden deafness was 1 month, and the conventional drug treatment was ineffective (the standard of ineffective treatment was that the average increase of impaired frequency hearing was less than 15dB after conventional treatment); 4 informed consent and signing of informed consent; 5 which can insist follow-up.

Exclusion criteria

Exclusion criteria: 1 deafness of any definite cause; 2 accompanied by heart disease, cerebral infarction, cerebral hemorrhage, hypertension, diabetes, abnormal coagulation, malignant diseases, hemodialysis, HBV, HCV and other serious diseases; 3 pregnancy or in 12 months pregnant women; 4 have high or unrealistic expectations for hearing improvement or recovery; 5 anxiety, depression or other history of mental illness; 6 blood system or other internal diseases cannot tolerate local anesthesia surgery; 7 previous diagnosis of immune-related diseases; 8 clinical examination data cannot be retained completely. 9 previous history of bilateral ear diseases affecting hearing; 10 allergic history of narcotic drugs.

Design outcomes

Primary

MeasureTime frame
hearing threshold;

Countries

China

Contacts

Public ContactBing Hu

Shenzhen Second People's Hospital

yahu1985@126.com+86 13302902055

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026